You have successfully sign out
Loading...
Immunome, Inc.
IMNM
Company Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
NASDAQ
Unprofitable
Unprofitable
8.79USD
0.25 ( 2.93%)
After-hours 8.53$
-0.26 (-2.96%)Market Closed (as of Apr 30, 20:00 EDT)
Relative Strenght
16
Volume Buzz
-8%
Earning Acce
No
Dist 52w H.
48%
